Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Cancer Center test helps reduce risk of death in advanced lung cancer

12.10.2011
Identifies key protein, boon for personalized medicine

Researchers at the University of Colorado Cancer Center have developed a test that identifies key biomarkers in advanced lung cancer that helped reduce the risk of death by 36 percent over a 30- month period in a recent clinical trial.

"We are moving from a one-size-fits-all model to more personalized medicine in lung cancer," said University of Colorado School of Medicine Professor Fred R. Hirsch, MD, Ph.D., a Cancer Center investigator who developed the test along with colleague Wilbur Franklin, MD. "This is a completely new paradigm in treating cancer."

The test was developed in 2003 when Hirsch and his colleagues created a scoring system ranging from 0 to 400 that identified patients with the highest levels of the protein Epidermal Growth Factor Receptor (EGFR). Those scoring over 200 had a better prognosis.

A clinical trial held in Europe known as the FLEX-study, found that 30 percent of the advanced lung cancer patients who took part had high levels of the EGFR protein identified by the University of Colorado Cancer Center test.

The trial consisted of 1,125 advanced lung cancer patients separated into two groups. One group received standard chemotherapy while the other had chemotherapy along with the drug cetuximab, an antibody that attaches to EGFR receptors atop lung cancer cells and often inhibits their growth.

The results were announced two weeks ago at the 2011 European Multidisciplinary Cancer Conference in Stockholm.

Using the Cancer Center test, the trial showed that Caucasian patients with an over expression of EGFR and treated with chemotherapy and cetuximab had a 36 percent reduction in deaths compared to the other group.

Cetuximab, or Erbitux, is primarily used to fight colo-rectal and head and neck cancers.

Hirsch, who discussed the study results at the Stockholm conference, said the test is another step toward finding the best, most effective therapy for each patient.

"With this personalized medicine we can identify subgroups of patients that can get better effects from certain drugs," he said. "In some cases there is a potential for a cure. Right now the cure rate for advanced lung cancer is two to three percent at best. This is a huge improvement but everything is based on the selection criteria."

The CU School of Medicine is a prominent leader in lung cancer research. D. Ross Camidge, MD, Ph.D., clinical director of the Thoracic Oncology Program at the University of Colorado Hospital and a Cancer Center investigator, has helped develop effective drug treatments for patients with the ALK gene rearrangement, an abnormality that occurs in three to five percent of lung cancer patients.

Hirsch is currently leading a clinical trial with colleagues in the Southwest Oncology Group that is similar to the European study. He hopes it will further validate the predictive value of the test in relation to using cetuximab in patients with advanced lung cancer. The study (SWOG 0819) has 550 participants and expects 1,500 total.

Hirsch's research laboratory specializes in identifying biomarkers which can predict benefits from new cancer drugs and place the right patients with the right therapy.

The results of the European trial are expected to be published in an upcoming edition of The Lancet Oncology.

The University of Colorado Cancer Center is Colorado's only National Cancer Institute-designated comprehensive cancer center. Headquartered on the University of Colorado Anschutz Medical Campus, the center is a consortium of three state universities (Colorado State University, University of Colorado at Boulder and University of Colorado Denver) and six institutions (Children's Hospital Colorado, Denver Health, Denver VA Medical Center, Kaiser Permanente Colorado, National Jewish Health and University of Colorado Hospital).

Together, our 440+ members work to relieve suffering from cancer by discovering, developing and delivering breakthroughs in the diagnosis, treatment and prevention of cancer for the citizens of Colorado, the region and beyond. Learn more at www.coloradocancercenter.org.

David Kelly | EurekAlert!
Further information:
http://www.ucdenver.edu
http://www.coloradocancercenter.org

More articles from Health and Medicine:

nachricht Using fragment-based approaches to discover new antibiotics
21.06.2018 | SLAS (Society for Laboratory Automation and Screening)

nachricht Scientists learn more about how gene linked to autism affects brain
19.06.2018 | Cincinnati Children's Hospital Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Temperature-controlled fiber-optic light source with liquid core

In a recent publication in the renowned journal Optica, scientists of Leibniz-Institute of Photonic Technology (Leibniz IPHT) in Jena showed that they can accurately control the optical properties of liquid-core fiber lasers and therefore their spectral band width by temperature and pressure tuning.

Already last year, the researchers provided experimental proof of a new dynamic of hybrid solitons– temporally and spectrally stationary light waves resulting...

Im Focus: Overdosing on Calcium

Nano crystals impact stem cell fate during bone formation

Scientists from the University of Freiburg and the University of Basel identified a master regulator for bone regeneration. Prasad Shastri, Professor of...

Im Focus: AchemAsia 2019 will take place in Shanghai

Moving into its fourth decade, AchemAsia is setting out for new horizons: The International Expo and Innovation Forum for Sustainable Chemical Production will take place from 21-23 May 2019 in Shanghai, China. With an updated event profile, the eleventh edition focusses on topics that are especially relevant for the Chinese process industry, putting a strong emphasis on sustainability and innovation.

Founded in 1989 as a spin-off of ACHEMA to cater to the needs of China’s then developing industry, AchemAsia has since grown into a platform where the latest...

Im Focus: First real-time test of Li-Fi utilization for the industrial Internet of Things

The BMBF-funded OWICELLS project was successfully completed with a final presentation at the BMW plant in Munich. The presentation demonstrated a Li-Fi communication with a mobile robot, while the robot carried out usual production processes (welding, moving and testing parts) in a 5x5m² production cell. The robust, optical wireless transmission is based on spatial diversity; in other words, data is sent and received simultaneously by several LEDs and several photodiodes. The system can transmit data at more than 100 Mbit/s and five milliseconds latency.

Modern production technologies in the automobile industry must become more flexible in order to fulfil individual customer requirements.

Im Focus: Sharp images with flexible fibers

An international team of scientists has discovered a new way to transfer image information through multimodal fibers with almost no distortion - even if the fiber is bent. The results of the study, to which scientist from the Leibniz-Institute of Photonic Technology Jena (Leibniz IPHT) contributed, were published on 6thJune in the highly-cited journal Physical Review Letters.

Endoscopes allow doctors to see into a patient’s body like through a keyhole. Typically, the images are transmitted via a bundle of several hundreds of optical...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Munich conference on asteroid detection, tracking and defense

13.06.2018 | Event News

2nd International Baltic Earth Conference in Denmark: “The Baltic Sea region in Transition”

08.06.2018 | Event News

ISEKI_Food 2018: Conference with Holistic View of Food Production

05.06.2018 | Event News

 
Latest News

Graphene assembled film shows higher thermal conductivity than graphite film

22.06.2018 | Materials Sciences

Fast rising bedrock below West Antarctica reveals an extremely fluid Earth mantle

22.06.2018 | Earth Sciences

Zebrafish's near 360 degree UV-vision knocks stripes off Google Street View

22.06.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>